Cargando…

Comparison of Immune Responses between Inactivated and mRNA SARS-CoV-2 Vaccines Used for a Booster Dose in Mice

A large amount of real-world data suggests that the emergence of variants of concern (VOCs) has brought new challenges to the fight against SARS-CoV-2 because the immune protection elicited by the existing coronavirus disease 2019 (COVID-19) vaccines was weakened. In response to the VOCs, it is nece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luan, Ning, Cao, Han, Wang, Yunfei, Lin, Kangyang, Hu, Jingping, Liu, Cunbao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301383/ https://www.ncbi.nlm.nih.gov/pubmed/37376650 http://dx.doi.org/10.3390/v15061351

Ejemplares similares

Comparison of the Immune Effects of an mRNA Vaccine and a Subunit Vaccine against Herpes Zoster Administered by Different Injection Methods
por: Lin, Kangyang, et al.
Publicado: (2023)

Evaluation of the Immunological Efficacy of an LNP-mRNA Vaccine Prepared from Varicella Zoster Virus Glycoprotein gE with a Double-Mutated Carboxyl Terminus in Different Untranslated Regions in Mice
por: Wang, Yunfei, et al.
Publicado: (2023)

Effects of Varicella-Zoster Virus Glycoprotein E Carboxyl-Terminal Mutation on mRNA Vaccine Efficacy
por: Cao, Han, et al.
Publicado: (2021)

Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro
por: Luan, Ning, et al.
Publicado: (2022)

An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines
por: Cao, Han, et al.
Publicado: (2021)

LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix™ in VZV-primed mice
por: Luan, Ning, et al.
Publicado: (2022)

Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine
por: Luan, Ning, et al.
Publicado: (2022)

Immunological evaluation of an mRNA vaccine booster in individuals fully immunized with an inactivated SARS‐CoV‐2 vaccine
por: Xu, Xingli, et al.
Publicado: (2022)

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
por: Kuhlmann, Constanze, et al.
Publicado: (2022)

mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
por: Zhang, Biyan, et al.
Publicado: (2022)

Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
por: Intapiboon, Porntip, et al.
Publicado: (2021)

New-onset MOGAD after first-dose SARS-CoV-2 mRNA vaccination with relapse following SARS-CoV-2 mRNA booster
por: Arismendez, Alan A., et al.
Publicado: (2023)

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
por: Zhan, Haoting, et al.
Publicado: (2023)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore
por: Ng, Oon Tek, et al.
Publicado: (2022)

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
por: Nanishi, Etsuro, et al.
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines
por: Di Giacomo, Anna M., et al.
Publicado: (2022)

Bilateral Branch Retinal Vein Occlusion after mRNA-SARS-CoV-2 Booster Dose Vaccination
por: Gironi, Matteo, et al.
Publicado: (2023)

Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
por: Özbay Kurt, Feyza Gül, et al.
Publicado: (2022)

Booster effect of the third dose of SARS-CoV-2 mRNA vaccine in Japanese kidney transplant recipients
por: Kawabe, Mayuko, et al.
Publicado: (2023)

Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains
por: Xiao, Chanchan, et al.
Publicado: (2022)

Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China
por: Tung, Tao-Hsin, et al.
Publicado: (2022)

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
por: Zuo, Fanglei, et al.
Publicado: (2022)

T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine
por: Sophonmanee, Ratchanon, et al.
Publicado: (2022)

Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study
por: Mondaca, Sebastián, et al.
Publicado: (2023)

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
por: Wu, Kai, et al.
Publicado: (2021)

Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice
por: Cao, Han, et al.
Publicado: (2021)

Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients
por: Patelli, Giorgio, et al.
Publicado: (2022)

Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine
por: Yigit, Metin, et al.
Publicado: (2022)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study
por: Dib, Martín, et al.
Publicado: (2022)

Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models
por: Li, Dandan, et al.
Publicado: (2021)

Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments
por: Piubelli, Chiara, et al.
Publicado: (2023)

IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers
por: Rasheed, Waleed S., et al.
Publicado: (2023)

A protein subunit vaccine booster following two doses of inactivated SARS-CoV-2 vaccine provides high neutralisation of SARS-CoV-2 and its variants in mice
por: Zhang, Rong, et al.
Publicado: (2022)

A SARS-CoV-2 Outbreak Among Nursing Home Residents Vaccinated with a Booster Dose of mRNA COVID-19 Vaccine
por: Ripabelli, Giancarlo, et al.
Publicado: (2022)

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
por: Li, Gen, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eukmkrkhocq56bldb8p2tdtp8n